文献速递血管炎

甲氧苄啶-磺胺甲噁唑预防与利妥昔单抗治疗的肉芽肿性多血管炎患者严重感染的关系

Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项回顾性队列研究纳入2011至2020年美国数据库中919例接受利妥昔单抗治疗的肉芽肿性多血管炎成人患者,评估甲氧苄啶-磺胺甲噁唑(TMP-SMX)预防与严重感染的关系。中位随访496天期间发生130例严重感染(发生率6.1/100人年,95%CI 5.0-7.4),时变TMP-SMX与严重感染呈负相关(aHR 0.5,95%CI 0.3-0.9),但可能与不良事件相关(aHR 1.3,95%CI 0.9-1.9)。

要点

  • 时变TMP-SMX与严重感染负相关(aHR 0.5,95%CI 0.3-0.9)。
  • 门诊感染aHR 0.8(95%CI 0.6-1.1),未达统计学显著。
  • TMP-SMX可能与不良事件相关(aHR 1.3,95%CI 0.9-1.9)。

核心结论

  • TMP-SMX预防与利妥昔单抗治疗的GPA患者严重感染减少相关,但可能增加不良事件,需进一步研究最佳预防策略。

研究设计与样本

  • 回顾性队列研究,纳入2011至2020年美国Merative™ Marketscan®研究数据库中首次(索引)利妥昔单抗治疗前参保≥6个月的GPA成人患者。
  • TMP-SMX预防定义为索引日期后或与索引日期重叠的≥28天处方配药。
  • 严重感染定义为住院主要诊断为感染(排除病毒或分枝杆菌编码)。
  • 采用Cox比例风险回归评估时变TMP-SMX与结局的关联,并调整潜在混杂因素。

主要发现

  • 共纳入919例接受利妥昔单抗治疗的个体(女性53%),平均(标准差)年龄52.1(16)岁,281例(31%)在索引日期30天内配药TMP-SMX。
  • 中位随访496天(四分位距138-979天)期间,104例个体发生130例严重感染,发生率为6.1/100人年(95%CI 5.0-7.4)。
  • 时变TMP-SMX与严重感染呈负相关(aHR 0.5,95%CI 0.3-0.9)。
  • 门诊感染的aHR为0.8(95%CI 0.6-1.1)。
  • 肺孢子菌肺炎(PJP)的估计不精确(13例事件,未调整HR 0.2,95%CI 0.03-1.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究最佳预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the association of trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis with serious infections in rituximab-treated patients with granulomatosis with polyangiitis (GPA). METHODS: This retrospective cohort study included adults with GPA (2011-2020) within the United States Merative™ Marketscan® Research Databases with ≥6 months' enrolment prior to first (index) rituximab treatment. We defined TMP-SMX prophylaxis as a ≥28-day prescription dispensed after or overlapping the index date. Serious infection was a hospital primary diagnosis for infection (excluding viral or mycobacterial codes). Secondary outcomes were outpatient infection, Pneumocystis jirovecii pneumonia (PJP) and adverse events potentially attributable to TMP-SMX. Cox proportional hazards regression assessed the association of time-varying TMP-SMX with outcomes of interest, adjusting for potential confounders. Individuals were followed until the outcome of interest, end of database enrolment or 31 Decamber 2020. RESULTS: Among 919 rituximab-treated individuals (53% female), mean (s.d.) age was 52.1 (16) years and 281 (31%) were dispensed TMP-SMX within 30 days of index date. Over a median of 496 (interquartile range 138-979) days, 130 serious infections occurred among 104 individuals (incidence 6.1 [95% CI: 5.0, 7.4] per 100 person-years). Time-varying TMP-SMX was negatively associated with serious infection (adjusted hazard ratio [aHR] 0.5; 95% CI: 0.3, 0.9). The aHR for outpatient infections was 0.8 (95% CI: 0.6, 1.1). The estimate for PJP was imprecise (13 events, unadjusted HR 0.2; 95% CI: 0.03-1.8). TMP-SMX was potentially associated with adverse events (aHR 1.3; 95% CI: 0.9, 1.9). CONCLUSIONS: TMP-SMX prophylaxis was associated with reduced serious infections in rituximab-treated GPA, but may increase adverse events, warranting further study of optimal prophylaxis strategies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Mendel A, Behlouli H, Vinet É, et al. Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab. Rheumatology (Oxford). 2025. PMID: 39024050. doi:10.1093/rheumatology/keae368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。